The drug achieved complete tumour responses in five out of 45 metastatic kidney cancer patients, compared to one in 25.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.